Leukemia · 2019 · 47 citations · 33 references
Life SciencesImmunologyOncologyCancer ImmunologyInnate ImmunitySignal TransductionCancer ImmunotherapyImmune Cell SignalingInflammatory SignalingInnate Immune ActivationInnate Immune Signaling PathwaysToll-like ReceptorsAdaptor Protein RecruitmentAdaptor Protein SignalingChronic Lymphocytic Leukemia TherapyMyd88-dependent SignalingMyeloid Differentiation Primary Response 88 SignalingStat3 SignalingTherapeutic Target IdentificationToll-like Receptor Signaling
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in Toll-like receptor (TLR) signal transduction and innate immune responses. Recruitment and subsequent activation of IRAK4 upon TLR stimulation is mediated by the myeloid differentiation primary response 88 (MYD88) adaptor protein. Around 3% of chronic lymphocytic leukemia (CLL) patients have activating mutations of MYD88, a driver mutation in this disease. Here, we studied the effects of TLR activation and the pharmacological inhibition of IRAK4 with ND2158, an IRAK4 competitive inhibitor, as a therapeutic approach in CLL. Our in vitro studies demonstrated that ND2158 preferentially killed CLL cells in a dose-dependent manner. We further observed a decrease in NF-κB and STAT3 signaling, cytokine secretion, proliferation and migration of primary CLL cells from MYD88-mutated and -unmutated cases. In the Eµ-TCL1 adoptive transfer mouse model of CLL, ND2158 delayed tumor progression and modulated the activity of myeloid and T cells. Our findings show the importance of TLR signaling in CLL development and suggest IRAK4 as a therapeutic target for this disease.
33
Restoring function in exhausted CD8 T cells during chronic viral infection
Daniel L. Barber, E. John Wherry, David Masopust et al. · Nature · 2005 · 4K citations
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Osamu Adachi, Taro Kawai, Kiyoshi Takeda et al. · Immunity · 1998 · 2K citations · Full text
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xosé S. Puente, Magda Pinyol, Vı́ctor Quesada et al. · Nature · 2011 · 1.5K citations · Full text
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo, Ryan M. Young, Roland Schmitz et al. · Nature · 2010 · 1.5K citations · Full text
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau, Scott L. Carter, Petar Stojanov et al. · Cell · 2013 · 1.4K citations · Full text